---
title: "賽諾菲在第三季度業績超預期後股價上漲，這主要得益於與 Regeneron 合作的 Dupixent 藥物"
description: "賽諾菲的股價在公佈超出預期的 2025 年第三季度業績後小幅上漲，主要得益於其哮喘藥物 Dupixent 的強勁銷售，該藥物創造了 42 億歐元的收入，同比增長 26%。總銷售額達到 124 億歐元，超出分析師的預期。儘管疫苗銷售下降了 8%，賽諾菲預計 2025 年將實現高單位數的銷售增長和低雙位數的每股收益增長。該公司正在與美國政策制定者就藥品定價進行討論，並擴大了其胰島素節省計劃，以改善獲取"
type: "news"
locale: "zh-HK"
url: "https://longbridge.com/zh-HK/news/262611409.md"
published_at: "2025-10-24T11:30:10.000Z"
---

# 賽諾菲在第三季度業績超預期後股價上漲，這主要得益於與 Regeneron 合作的 Dupixent 藥物

> 賽諾菲的股價在公佈超出預期的 2025 年第三季度業績後小幅上漲，主要得益於其哮喘藥物 Dupixent 的強勁銷售，該藥物創造了 42 億歐元的收入，同比增長 26%。總銷售額達到 124 億歐元，超出分析師的預期。儘管疫苗銷售下降了 8%，賽諾菲預計 2025 年將實現高單位數的銷售增長和低雙位數的每股收益增長。該公司正在與美國政策制定者就藥品定價進行討論，並擴大了其胰島素節省計劃，以改善獲取渠道

Sanofi (NASDAQ:SNY) shares traded slightly higher in Paris on Friday after the French drugmaker reported better-than-expected Q3 2025 financial results, thanks mainly to its asthma drug Dupixent, which is marketed in collaboration with Regeneron (NASDAQ:REGN). The Paris-based firm posted €12.4B ($14.4B) in sales and €2.91 ($3.38) of business earnin...

### Related Stocks

- [SNYNF.US - 賽諾菲](https://longbridge.com/zh-HK/quote/SNYNF.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| 4-Sanofi ousts CEO Hudson after stalled turnaround at vaccine giant | Sanofi has ousted CEO Paul Hudson after a six-year tenure marked by a stalled turnaround and pressure on vaccine sales.  | [Link](https://longbridge.com/zh-HK/news/275748711.md) |
| 17:31 ETAtopic Dermatitis Market to Accelerate at a Rapid Pace by 2034 with Advancements in Biologics and JAK Inhibitors \| DelveInsight | The atopic dermatitis market is projected to grow significantly by 2034, driven by the introduction of new therapies and | [Link](https://longbridge.com/zh-HK/news/276080710.md) |
| BUZZ-Upstream Bio jumps as experimental asthma drug shows promise in mid‑stage study | Shares of Upstream Biosurged 20% to $32.64 in premarket trading following positive results from a mid-stage study of its | [Link](https://longbridge.com/zh-HK/news/275596211.md) |
| Upstream Bio's Selloff May Be 'Overdone,' But Analyst Highlights Asthma Drug's Competitive Edge Concerns | Upstream Bio Inc. (NASDAQ:UPB) shares fell over 54% following mixed results from its asthma drug trials, despite analyst | [Link](https://longbridge.com/zh-HK/news/275923255.md) |
| Forget AI stocks: This pharma giant is using AI to dominate drug discovery | And there's more than one way to monetize this technology. | [Link](https://longbridge.com/zh-HK/news/276017486.md) |

---

> **免責聲明**：本文內容僅供參考，不構成任何投資建議。